PFM-1

........10........20........30........40........50........60........70........80........90.......100.......110.......120.......130.......140.......150.......160.......170.......180.......190.......200.......210.......220.......230.......240.......250... MKVINILSAVSMFCITCQALANDINLTLTHFKGPLYIVEDKEYVQENSMVYIGAQDITIIGATWTPATAEKLEQEIRKISSLPIKEVINTNYHTDRAGGNAYWKKLGASIVSTQMTYDLEKTNWRGIVDFTRQGMEHYPVLEQSLPDQVYPGDFALQNGHVRALYLGASHTEDGIFVYFPEERVLYGNCILKEKLGNMTFANRSEYPKTLKKLQGLIRSGELSVEAIIAGHNSPIQSVELIDHYLNLLEHGEQ

PFM-2	..L......I.LA...S.VF..QSD...I........................E.H..V.....................P......................R.................SQ..S...........................................................................................S....P..............................	91.70 %
PFM-3	..L......I.LA...S.VF..QSD...........V..............V...H..V.....................P........................................SQ..S...........................................................................................S....P..............................	92.09 %
PFM-4	..L.....VI.LA...S.VF..KSD..........................V.E.H..V.....................P........................................SQ..S.............I............N.D...................................................................P.............N........T.......	90.12 %

Last updated: November 20, 2024.

If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.

The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).

Contact: contact@bldb.eu

Live statistics (since December 3rd, 2023)